

Drug Class: Dual GIP/GLP-1 Receptor Agonist
Active Substance: Tirzepatide
Strength: 5 mg/vial
Form: Lyophilized Powder
Amount: 2 mL Vial
Active Life: Approx. 5–7 days
Average Dose: 1–5 mg per week (research protocols)
Liver Toxicity: None
Aromatization Rate: None
Anabolic Rate: Indirect metabolic effects only
Androgenic Rate: None
Manufacturer: Peptide Hubs
Laboratory Test: View Result
Tirzep 5 mg by Peptide Hubs contains lyophilized Tirzepatide, a cutting-edge peptide known for its potent dual agonist effects on the GIP and GLP-1 receptors. Originally developed for type 2 diabetes management, Tirzepatide has gained popularity among researchers studying weight loss, insulin sensitivity, and appetite regulation. Each vial contains 5 mg of pure compound, ideal for scientific studies and experimental use.
Unlike GLP-1 agonists alone, Tirzepatide binds to both GIP and GLP-1 receptors, leading to superior glucose control and enhanced satiety. This dual action helps reduce HbA1c levels and body weight more effectively than traditional incretin-based therapies. According to peer-reviewed clinical studies, Tirzepatide has demonstrated significant results in both diabetic and non-diabetic subjects.
Researchers exploring metabolic disorders, obesity models, and insulin resistance may find Tirzep an ideal peptide. Its extended half-life (up to one week) makes it suitable for weekly administration protocols. For enhanced results in combination studies, investigators often explore synergistic use alongside AOD-9604 for lipolytic action or Semax for cognitive impact studies.
Peptide Hubs guarantees the highest purity with validated lab testing. Manufactured under strict sterile conditions and vacuum-sealed for stability, Tirzep 5 mg meets the demands of serious research facilities in the USA. For full specs and formulation details, view our research-grade Tirzepatide listing.
Peptide Hubs remains a top-tier destination for novel peptides like Tirzep due to its competitive pricing, transparency, and fast shipping from USA-based warehouses. If you're looking for reliable sourcing for GIP/GLP-1 receptor research, this Tirzepatide formulation delivers consistent results.
It stimulates both GIP and GLP-1 receptors to regulate blood sugar, suppress appetite, and promote fat loss. It is currently studied for diabetes and obesity.
Tirzepatide targets both GIP and GLP-1 receptors, while Semaglutide targets only GLP-1. This dual action makes Tirzepatide potentially more effective in certain models.
Yes, for research purposes only. It is not approved for over-the-counter or personal use without a prescription.
Store lyophilized Tirzepatide in a fridge (2–8°C). Once reconstituted, keep it refrigerated and use within 30 days.
Please log in to write Tirzep 5 mg review.
Drug Class: GLP-1/GIP Receptor Agonist
Active Substance: Tirzepatide
Strength: 20 mg/vial
Form: Lyophilized Powder
Amount: 2 mL Vial
Active Life: 6–7 days
Average Dose: 5–15 mg per week
Liver Toxicity: None
Aromatization Rate: None
Anabolic Rate: None
Androgenic Rate: None
Manufacturer: Stealth Labs
Laboratory Test: View Result
Shipped Without Label!
Drug Class: Dual GLP-1/GIP Receptor Agonist
Active Substance: Tirzepatide
Strength: 5 mg/vial
Form: Lyophilized Powder
Amount: 2 mL Vial
Active Life: ~5–7 days
Average Dose: 2.5–5 mg subcutaneously per week
Liver Toxicity: None
Aromatization Rate: None
Anabolic Rate: Indirect via weight reduction
Androgenic Rate: None
Manufacturer: Dragon Pharma
Laboratory Test: View Result
Drug Class: GLP-1/GIP Receptor Agonist
Active Substance: Tirzepatide
Strength: 5 mg/vial
Amount: 2 mL Vial
Active Life: ~5–7 days
Average Dose: 2.5–15 mg per week
Liver Toxicity: None
Aromatization Rate: None
Anabolic Rate: N/A
Androgenic Rate: None
Manufacturer: Kalpa Pharmaceuticals